Cover Image
市場調查報告書

膽固醇酯傳輸蛋白質 (脂質傳輸蛋白質,CETP) - 開發中產品分析

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 358691
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
膽固醇酯傳輸蛋白質 (脂質傳輸蛋白質,CETP) - 開發中產品分析 Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 48 Pages
簡介

膽固醇酯傳輸蛋白質 (CETP) ,又稱為血漿脂質傳輸蛋白質,是促進膽固醇酯的傳輸的血漿蛋白質。

本報告提供膽固醇酯傳輸蛋白質 (脂質傳輸蛋白質,CETP)的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 各單劑/聯合治療
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Chong Kun Dang Pharmaceutical Corp.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1073TDB

Summary:

According to the recently published report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2017'; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic.

The report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2017' outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular and Metabolic Disorders which include indications Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease, Coronary Disease and Hyperlipidemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
  • The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Overview
    • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Chong Kun Dang Pharmaceutical Corp
    • Kowa Co Ltd
    • Pfizer Inc
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles
    • AMG-899 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-508 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalcetrapib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-16 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04445597 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Products
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial
      • Mar 07, 2017: DalCor's Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule
      • Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans
      • Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
      • Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
      • Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
      • Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
      • Jun 03, 2015: Dezima Pharma's CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet
      • Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease
      • Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein (a) Levels
      • Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia
      • Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995
      • Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995
      • Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001
      • Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Amgen Inc, H2 2017
  • Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Pipeline by Kowa Co Ltd, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017
  • Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top